Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. METHODS: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). RESULTS: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. CONCLUSIONS: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subset of those suffering from Major Depressive Disorder (MDD) achieve remission with antidepressant medication (ADM)1.”
From The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse (2020) · cites this paper as [1]
In the citing paper
“about onethird receive no benefit from two or more pharmacologic treatments (Rush et al., 2006;Trivedi et al., 2006).”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Rush et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationCUMULATIVE ILLNESS RATING SCALE
LINN, B. S., LINN, M. W., & GUREL, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,304
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationAgency for Health Care Policy and Research
Eisenberg, J. M. (1999) · Medical Care · doi:10.1097/00005650-199903000-00001 · Cited by 1,369
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citation
Research works printed but not linked: 4
- Agency for Health Care Policy and Research. Depression in primary care. Vol. 2. Treatment of major depression. Rockville, Md.: Department of Health and Human Services, 1993. (AHCPR publication no. 93-0551.)
- Fava M, 2000, J Clin Psychiatry, 61, 10
- Joffe RT, 1996, J Clin Psychiatry, 57, 114
- Fava M, 2003, Ann Clin Psychiatry, 15, 17, 10.3109/10401230309085666 · doi:10.3109/10401230309085666 · Paper page
Cited by
Items 601–700 of 999
Antidepressants versus interpersonal psychotherapy in treating depression in HIV-positive patients.
Moosa, M. Y. H., & Jeenah, F. Y. (2012) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v18i2.331 · Cited by 14
Pharmacological treatment approaches to difficult‐to‐treat depression
Chan, H., Mitchell, P. B., Loo, C. K. A., & Harvey, S. B. (2013) · The Medical Journal of Australia · doi:10.5694/mja12.10495 · Cited by 14
Electroconvulsive Therapy in the Treatment of Mood Disorders: One-Year Follow-up
Çakır, S., & Çağlar, N. (2016) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2016.14845 · Cited by 12
“INTRODUCTON The efficacy of pharmacotherapy in mood disorders is not satisfactory, and the desired remission rates are not currently achieved in either unipolar (UD) or bipolar disorders (BP) (1,2,3).”
BackgroundKöhler‐Forsberg, O., Larsen, E. R., Buttenschøn, H. N., Rietschel, M., Hauser, J., Souery, D., Maier, W., FARMER, A. E., McGuffin, P., Aitchison, K. J., et al. (2019) · The British Journal of Psychiatry · doi:10.1192/bjp.2018.302 · Cited by 11
“This includes dose increase, 5 augmentation 6 or switching to another antidepressant, 7 with the latter including switching within the same class 8 or to a different class of antidepressants.”
Neuropharmacology of Secondary Metabolites from Plants with Anxiolytic and Antidepressant Properties
García-Ríos, R. I., Mora-Pérez, A., Ramos-Molina, A. R., & Soria-Fregozo, C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.90919 · Cited by 19
“However, up to 70% of depressed patients have residual symptoms [5], and few options exist for transitioning treatment-resistant sufferers to alternative therapies that operate through distinct mechanisms [6].”
BackgroundThe Massachusetts General Hospital Guide to Depression: New Treatment Insights and Options
(2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1 · Cited by 12
Bupropion: efficacy and safety in the treatment of depression.
Ruiz, J. S., Gibert, J., Fraile, M., Bobes, J., Vallejo, J., Iglesias, C., & Iriarte, V. (2011) · Actas Españolas de Psiquiatría · Cited by 12
The Impact of Nonclinical Factors on Care Use for Patients with Depression: A STAR*D Report
Kashner, T. M., Trivedi, M. H., Wicker, A. B., Fava, M., Wisniewski, S., & Rush, A. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00091.x · Cited by 13
Self-citationIs evidence sufficient for evidence-based medicine?
Möller, H. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0048-7 · Cited by 11
“algorithms [1, 2, 46, 51] in methodologically stringent studies (e.”
Nakagawa, A., Sado, M., Mitsuda, D., Fujisawa, D., Kikuchi, T., Abe, T., Sato, Y., Iwashita, S., Mimura, M., & Ono, Y. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-006359 · Cited by 12
Alcohol Use Disorder as a Possible Predictor of Electroconvulsive Therapy Response
Aksay, S. S., Hambsch, M., Janke, C., Bumb, J. M., Kranaster, L., & Sartorius, A. (2016) · Journal of Ect · doi:10.1097/yct.0000000000000366 · Cited by 11
Pharmacotherapy Strategies for Treatment-Resistant Depression
Howland, R. H. (2006) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20061101-02 · Cited by 11
Aripiprazole Augmentation of Tranylcypromine in Treatment-Resistant Major Depression
Goforth, H. W., & Carroll, B. T. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000264970.54711.43 · Cited by 11
Bareš, M., Novák, T., Kopeček, M., Stopková, P., Cermak, J. K., Kožený, J., & Höschl, C. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.674533 · Cited by 10
“The ADs that had been ineffective in the treatment of the current episode were excluded and within-class change of antidepressants was not allowed with the exception of selective serotonin reuptake inhibitors (SSRIs) since the demonstrated effi cacy of withinclass change of SSRIs was comparable to acrossclass changes…”
ResultKey, A. P. F., Thornton‐Wells, T. A., & Smith, D. G. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.1055685 · Cited by 12
“, 1996) do not respond, are treatmentresistant, or have persistent deficits that detract from daily functioning (Kessler et al., 2003; Rush et al., 2006).”
BackgroundWang, L., Chen, F., Zhang, Y., & Ye, M. (2023) · Safety and Health at Work · doi:10.1016/j.shaw.2023.10.002 · Cited by 12
“The early state of depression is DS. DS include low mood, reduced enjoyment, increased fatigue, hopelessness and sleep dif fi culties, which often persist or fl uctuate, and a large proportion of patients do not respond to standard treatment [12].”
BackgroundShelton, R., Hollon, S., Wisniewski, S., Alpert, J., Balasubramani, G., Friedman, E., Rush, A., Trivedi, M., & Preskorn, S. (2009) · CNS Spectrums · doi:10.1017/s1092852900023555 · Cited by 11
Self-citationAmbulatory Clinical Pharmacy Specialty Services: The Kaiser Permanente Colorado Experience
Hill, R. R., Herner, S. J., Delate, T., & Lyman, A. E. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.3.245 · Cited by 13
Alpha Wavelet Power as a Biomarker of Antidepressant Treatment Response in Bipolar Depression
Jernajczyk, W., Gosek, P., Łątka, M., Kozłowska, K., Święcicki, Ł., & West, B. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_180 · Cited by 10
“The usual strategy is either to switch medications or add a drug with a different mechanism of action (MOA) (Stahl and Grady 2003).”
Yoshinaga, H., Nishida, T., Sasaki, I., KATO, T., Oki, H., Yabuuchi, K., & Toyoda, T. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.008 · Cited by 9
Whose depression deteriorates during acute phase antidepressant treatment?
Akechi, T., Sugishita, K., Chino, B., Itoh, K., Ikeda, Y., Shimodera, S., Yonemoto, N., Miki, K., Ogawa, Y., Takeshima, N., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.052 · Cited by 12
Senese, N. B., & Rasenick, M. M. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.120.000226 · Cited by 10
Pharmacotherapy and psychotherapy of pediatric depression
Maalouf, F. T., & Brent, D. A. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.496451 · Cited by 11
“No studies in adolescents have looked at subsequent steps, but the STAR*D study showed that with subsequent medication switches and augmentation, 67% of patients can eventually attain remission [75,76].”
BackgroundZajecka, J., & Zajecka, A. (2014) · Psychiatric Annals · doi:10.3928/00485713-20141106-07 · Cited by 11
Epileptic seizures, coma and EEG burst‐suppression from suicidal bupropion intoxication
Noda, A. H., Schu, U., Maier, T., Knake, S., & Rosenow, F. (2017) · Epileptic Disorders · doi:10.1684/epd.2017.0896 · Cited by 12
Haro, J. M., Lamy, F.-X., Jönsson, B., Knapp, M. R. J., Brignone, M., Caillou, H., Chalem, Y., Hammer-Helmich, L., Rive, B., & Saragoussi, D. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1657-3 · Cited by 14
“Switching antidepressants has been demonstrated to be effective in a number of clinical studies, with remission rates of up to 42% achieved in patients who previously failed to achieve remission [14, 15, 33].”
BackgroundProtein Biomarkers in Major Depressive Disorder: An Update
Woods, A. G., Wormwood, K. L., Iosifescu, D. V., Murrough, J. W., & Darie, C. C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-15950-4_35 · Cited by 12
Depression in Primary Care: Evidence and Practice
Elliott, R. L. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511861147 · Cited by 9
Nordstrom, G., Despiégel, N., Marteau, F., Danchenko, N., & Maman, K. (2010) · Journal of Medical Economics · doi:10.3111/13696998.2010.506371 · Cited by 10
Depression — Augmentation or Switch after Initial SSRI Treatment
van Elst, L. T., Ebert, D., & Hesslinger, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmc066200 · Cited by 9
Earleywine, M., Altman, B. R., & De Leo, J. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1912863 · Cited by 9
“Up to 30% of depression cases are “treatment resistant,” requiring more than two medications (Rush et al. 2006).”
BackgroundGPR55: Physiological functions and therapeutic potential in depression
Miao, Y., Cheng, Y.-Y., & Guan, W. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117113 · Cited by 10
Strategies for the Prevention and Treatment of Suicidal Behavior
Clayton, P. J., & Auster, T. L. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.1.foc15 · Cited by 9
Zhu, Y., Zhang, N., Ren, D., Bi, Y., Xu, F., Niu, W., Sun, Q., Guo, Z., Yuan, R., Yuan, F., et al. (2019) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000322 · Cited by 9
Hen-Shoval, D., Weller, A., Weizman, A., & Shoval, G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19010523 · Cited by 10
“Although international practice guidelines recommend that pharmacotherapy for adolescents should be initiated with fluoxetine, with sertraline or citalopram used in case of non-response to fluoxetine [61], after unsuccessful treatment for depression with an SSRI, it is unclear whether switching to a particular antidep…”
BackgroundA Southeast Asia Consensus on the Definition and Management of Treatment-Resistant Depression
Tor, P. C., Amir, N., Fam, J., Ho, R., Ittasakul, P., Maramis, M. M., Ponio, B., Purnama, D. A., Rattanasumawong, W., Rondain, E., et al. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s380792 · Cited by 14
Thase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., et al. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.1.foc104 · Cited by 9
Self-citationDepressive Status in Patients With Chronic Thromboembolic Pulmonary Hypertension
Funabashi, S., Kataoka, M., Inami, T., Kikuchi, T., Yanagisawa, R., Ishiguro, C., Okamoto, S., Yoshino, H., Watanabe, K., & Satoh, T. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0197 · Cited by 9
Are omega-3 fatty acids efficacious in the treatment of depression? A review
Lange, K. W., Nakamura, Y., Zhao, H., Bai, D., & Wang, H. (2021) · Journal of Food Bioactives · doi:10.31665/jfb.2021.14265 · Cited by 9
“Approximately 30% of individuals treated for depression remain refractory to multistep antidepressant therapies (Rush et al., 2006a; Rush et al., 2006b).”
BackgroundCraig, T., Grossman, S., Bromet, E. J., Fochtmann, L. J., & Carlson, G. A. (2007) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2007.06.005 · Cited by 9
Wang, C., Lan, X., Liu, W., Zhan, Y., Zheng, W., Chen, X., Liu, G., Mai, S., Lu, H., McIntyre, R. S., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03027-2 · Cited by 10
Wang, Z., Li, X., Li, N., Huang, L., Liu, J., Yang, B., Jingquan, S., Fei, Y., Ji, X., Gao, K., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00570 · Cited by 9
“In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trials, only about one-half of patients responded, and one-third of remitted with the first level of antidepressant treatments (5, 6).”
BackgroundHejzlar, M., Novák, T., & Bareš, M. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s303226 · Cited by 9
Mayes, T. L., Deane, A. E., Aramburu, H., Yagnik, K., & Trivedi, M. H. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.002 · Cited by 9
Self-citationSzmulewicz, A., Valerio, M. P., Lomastro, J., & Martino, D. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.11.044 · Cited by 7
Depression and antidepressant prescribing in the elderly
Herron, J. W., & Mitchell, A. (2018) · Prescriber · doi:10.1002/psb.1654 · Cited by 9
Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K. J., Lux, L. J., Noord, M. V., Mager, U., Gaynes, B. N., Thieda, P., Strobelberger, M., et al. (2011) · Cited by 8
Integrating EMDR into an evolutionary‐based therapy for depression: a case study
Krupnik, V. (2015) · Clinical Case Reports · doi:10.1002/ccr3.228 · Cited by 10
Fowler, S. M., Guerini, E., Qiu, N., Cleary, Y., Parrott, N. J., Greig, G., & Mallalieu, N. L. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.237214 · Cited by 9
“D study) showed that only one-third of patients achieved remission with initial treatment, and remission rates declined even further with each successive treatment attempt (Rush et al., 2006).”
BackgroundTherapie depressiver Störungen mit selektiven Serotonin-Rückaufnahme-Inhibitoren (SSRI)
Novak, W., & Erfurth, A. (2017) · psychopraxis neuropraxis · doi:10.1007/s00739-016-0371-5 · Cited by 8
Lloret‐Linares, C., Daali, Y., Chevret, S., Nieto, I., Molière, F., Courtet, P., Galtier, F., Richieri, R. M., Morange, S., Llorca, P., et al. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0173-2 · Cited by 8
“It provides a reasonable second-step choice for patients with depression and is used extensively in psychiatric practice [24, 25].”
Treatment-Resistant Depression
Cusin, C., & Peyda, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_1 · Cited by 8
STAR*D: a summary and UK perspective
Deakin, J., & O’Loughlin, C. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109104886 · Cited by 8
Dépression résistante : les stratégies de changement et d’association de médicaments antidépresseurs
Charpeaud, T., Molière, F., Bubrovszky, M., Haesebaert, F., Allaïli, N., Bation, R., Nieto, I., Richieri, R. M., Saba, G., Bellivier, F., et al. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.02.003 · Cited by 13
Developing the evidence for evidence-based practice
Rush, A. J. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080202 · Cited by 8
Self-citationKim, S., LeBlanc, A. J., Morris, P., Simon, G., & Walter, J. (2011) · SSRN Electronic Journal · doi:10.2139/ssrn.2019782 · Cited by 8
“Simon, Ludman, and Rutter (2009); Simon et al. (2004). Miranda et al.”
Current drug targets for the treatment of depression
Pathak, G., Nigade, A., Anitha, K., & Bhatt, S. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100270 · Cited by 8
Uso de antidepressivos e percepção de saúde entre adultos de 40 anos ou mais: estudo longitudinal.
Menolli, P. V. D. S., Garso, P. A. G., Guidoni, C. M., & Girotto, E. (2020) · Revista Colombiana de Ciencias Químico Farmacéuticas · doi:10.15446/rcciquifa.v49n1.85776 · Cited by 12
Cost-Effective Drug Switch Options After Unsuccessful Treatment With an SSRI for Depression.
Singh, A., Brooks, M., Voorhees, R., Potter, M. A., Roberts, M., Luther, J., & Wisniewski, S. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201500448 · Cited by 9
Self-citationWhole-body edema with olanzapine: A case report and literature review
Cook, E. A., Shipman, D., & Fowler, T. G. (2020) · Mental Health Clinician · doi:10.9740/mhc.2020.09.291 · Cited by 7
“The commonly accepted definition of treatment-resistant depression (TRD) is the failure to achieve a clinically meaningful response after a trial of 2 or more antidepressant agents, prescribed in adequate doses, for an adequate treatment duration and affirmation of treatment adherence.(1,4) In persons with TRD who exh…”
BackgroundSITAgliptin for Depressive Symptoms in Type 2 Diabetes: A Feasibility Randomized Controlled Trial
Moulton, C. D., Rokakis, A. S., Pickup, J. C., Young, A. H., Stahl, D. R., & Ismail, K. (2021) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000985 · Cited by 10
Sex-Specific Retinal Anomalies Induced by Chronic Social Defeat Stress in Mice
Arsenault, E., Lavigne, A.-A., Mansouri, S., Gagné, A.-M., Francis, K., Bittar, T. P., Quessy, F., Abdallah, K., Barbeau, A., Hébert, M., et al. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.714810 · Cited by 7
Rethorst, C. D., Trombello, J. M., Chen, P. M., Carmody, T. J., Lazalde, A., & Trivedi, M. H. (2023) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2023.101103 · Cited by 6
Self-citationComparing outcomes of adjunctive treatment in depression: Aripiprazole versus Bupropion
Nasr, S. J., Wendt, B., Popli, A., & Crayton, J. W. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.03.019 · Cited by 10
“Furthermore, the longer patients stayed in the trial, the less likely they were to respond to medication (Fava et al., 2006; McGrath et al., 2006; Nierenberg et al., 2006; Rush et al., 2006; Thase et al., 2007; Trivedi et al., 2006a).”
BackgroundBrain Stimulation, Revolutions, and the Shifting Time Domain of Depression
George, M. S., & Sackeïm, H. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.07.013 · Cited by 9
Bao, S., Wen, J. M., Lin, Q., Li, Y., Huang, Y., Zhou, H.-Y., & Hu, G. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13081 · Cited by 7
Neurostimulation therapies in major depressive disorder: A decision‐analytic model
Teng, M., Khoo, A. L., Zhao, Y. J., Abdin, E., Mok, Y. M., Lim, B. P., & Tor, P. C. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.13091 · Cited by 8
The STAR*D trial: the 300 lb gorilla is in the room, but does it block all the light?
Hatcher, S. (2008) · Evidence-Based Mental Health · doi:10.1136/ebmh.11.4.97 · Cited by 7
“to change to sertraline, bupropion-SR or venlafaxine-XR.(2) A quarter of these”
BackgroundGuico‐Pabia, C. J., Jiang, Q. L., Ninan, P. T., & Thase, M. E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.605114 · Cited by 6
“Days 15 to 30 n1⁄4 159 n1⁄4 177 n1⁄4 148 n1⁄4 484 Any adverse event, n (%) 54 (34) 54 (31) 54 (37) 162 (33) Headache 10 (6) 15 (9) 15 (10) 38 (8)”
Self-citationDemitrack, M. A. (2007) · Psychopharm Review · doi:10.1097/01.idt.0000271143.75925.33 · Cited by 8
Depression Screening, Diagnosis, and Treatment Across the Lifespan
Cozine, E. W., & Wilkinson, J. M. (2016) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2016.02.004 · Cited by 10
“In general, if there has been no response to the initial therapy, consider switching to another monotherapy as the next step.(55) If there has been a partial response, consider augmentation of the first medication with a second.”
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Genetically encoded sensors for in vivo detection of neurochemicals relevant to depression
Zhao, Y., Wan, J., & Li, Y. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16046 · Cited by 7
The use of sequential pharmacotherapy for the treatment of acute major depression: a scoping review
Jones, B. D. M., Husain, M. I., & Mulsant, B. H. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1878144 · Cited by 7
Sado, M., Koreki, A., Ninomiya, A., Kurata, C., Mitsuda, D., Sato, Y., Kikuchi, T., Fujisawa, D., Ono, Y., Mimura, M., et al. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13298 · Cited by 8
The relationship of antidepressant prescribing concentration to treatment duration and cost.
Hodgkin, D., Merrick, E. L., & Hiatt, D. P. (2012) · PubMed · Cited by 6
Pasten, C. S., & Caneo, C. (2022) · Medwave · doi:10.5867/medwave.2022.01.002146 · Cited by 7
Singh, K. P., Singh, P., Agrawal, P., & Agarwal, B. (2023) · Journal of Applied Biology & Biotechnology · doi:10.7324/jabb.2023.11502 · Cited by 6
“However, patients with major depression have inadequate responses or intolerant side effects to first-line treatment with SSRIs and SNRIs frequently prescribed with atypical ADs [16].”
BackgroundKATO, T., Matsumoto, Y., Yamamoto, M., Matsumoto, K., Baba, S., Nakamichi, K., Matsuda, H., Nishimuta, H., & Yabuuchi, K. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.142 · Cited by 8
“Although SSRIs and SNRIs have dramatically expanded treatment options for major depressive disorder, there is still a significant unmet medical need for management of this disorder, including therapeutics delayed onset, and treatment resistance (Rush et al. 2006; Warden et al. 2007; Reeves et al. 2008; Gelenberg et al…”
BackgroundWhat is an animal model of a neuropsychiatric disorder?
Hoffman, K. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-08-100099-1.00001-7 · Cited by 5
After the failure of citalopram for depression, what next?
Doggrell, S. A. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.11.1515 · Cited by 7
“In the switch part of the STAR*D study [4], the 727 participants were predominantly white (76%) and had suffered from depression since they were a mean of 25 years of age, with episodes experienced over a period of 16 years.”
BackgroundPractical Clinical Trials in Psychopharmacology: A Systematic Review
Vitiello, B. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000295 · Cited by 7
“Some of the identified PCTs have addressed critical issues of psychiatric care, such as the choice of antipsychotic 20,32 or antidepressant medication, 29,30,42 prevention of suicide, 25 or major safety concerns.”
for the SUN(^_^)D Investigators, Yonemoto, N., Tanaka, S., Furukawa, T. A., Kato, T., Mantani, A., Ogawa, Y., Tajika, A., Takeshima, N., Hayasaka, Y., et al. (2015) · Trials · doi:10.1186/s13063-015-0985-6 · Cited by 6
“Frequency, intensity, and burden of side effects rating The Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) was originally used in STAR*D [8, 9] as a global rating scale for side effects.”
MethodDouble-blind switch study of vilazodone in the treatment of major depressive disorder
Grant, J. E., Redden, S. A., & Leppink, E. W. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000166 · Cited by 6
Comorbidity of Alcohol Use Disorder and Depression: A Case Report and Review of the Literature
Tseng, I., Ganz, A., Mitton, A. G., & TSUANG, J. W. (2017) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0000000000000106 · Cited by 9
Secular, Non-dogmatic Spirituality
Walach, H. (2014) · Studies in neuroscience, consciousness and spirituality · doi:10.1007/978-3-319-09345-1_5 · Cited by 6
Yoon, H. S., Hattori, K., Sasayama, D., & Kunugi, H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.039 · Cited by 6
Seetasith, A., Greene, M., Hartry, A., & Burudpakdee, C. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s220007 · Cited by 6
Treatment of depression: antidepressant monotherapy and combination therapy.
Cascade, E. F., Kalali, A. H., & Blier, P. (2007) · PubMed Central · Cited by 6
El-Magd, R. M. A., Obuobi-Donkor, G., Adu, M. K., Lachowski, C., Duddumpudi, S., Lawal, M. A., Sapara, A. O., Achor, M., Kouzehgaran, M., Hegde, R., et al. (2020) · JMIR Research Protocols · doi:10.2196/18843 · Cited by 6
“The reported results of the STAR*D study are the most vivid example of this clinical phenomenon [10-16].”
BackgroundAlexander, J. L., Richardson, G., Grypma, L., & Hunkeler, E. M. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.11s.s59 · Cited by 6
Levine, S. B. (2007) · Journal of Sex & Marital Therapy · doi:10.1080/00926230701480349 · Cited by 6
“Evidence from both clinical experience and the recent government-funded research on less highly selected patients—STARD and CATIE trials—shows that there is much less to cheer about (Essock, Covell, Davis, Stroup, Rosenbeck, & Lieberman, 2006; Insel, 2006; Rush et al., 2006).”
MethodThe Search for Improved Antidepressant Strategies: Is Bigger Better?
Coryell, W. H. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11030510 · Cited by 6
What's new in the other general journals
Tonks, A. (2006) · BMJ · doi:10.1136/bmj.332.7536.289 · Cited by 6
Antidepressants do work after all
Young, A. H., & Moulton, C. D. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120933127 · Cited by 6
“The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial was carried out in the United States and is frequently cited as a benchmark for response rates to antidepressant therapy (Rush et al., 2006).”
BackgroundHe, Y., Wang, X., Wang, Z., Zhang, P., Huang, X., Yu, M., Murphy, J., Michalak, E., Liu, J., Yang, T., et al. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s468332 · Cited by 5
“10 Moreover, many patients also suffer from the side effects of antidepressants, making it harder for psychiatrists to adjust the prescription.”
BackgroundWang, P., Gao, Y., Li, H., Tian, J., Chai, S., Zhou, Z., Huang, X., Bao, W., Hu, X., Zhang, L., et al. (2025) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13918 · Cited by 7
“1,2 3 – 8 These interventions are especially valuable given that at least one-third of patients fail to achieve an adequate response to fi rst-line treatments like pharmacotherapy and psychotherapy, 9 noninvasive neuromodulation represents a valuable alternative.”
Predicting Outcomes of Antidepressant Treatment in Community Practice Settings
Simon, G. E., Cruz, M., Boggs, J. M., Beck, A. L., Shortreed, S. M., & Coley, R. Y. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20230380 · Cited by 5
Consistent differential effects of bupropion and mirtazapine in major depression
Strobl, E. V. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119551 · Cited by 8
A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult
Blaszczyk, A. T., Mathys, M. L., & Le, J. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01051-3 · Cited by 9
Metadata
- Authors
- Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., Shores-Wilson, K., Niederehe, G., & Fava, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- New York State Psychiatric Institute (US)
- Massachusetts General Hospital (US)
- National Institute of Mental Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1231-1242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140787893
- Cited by
- 1,033
- References
- 44
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 28 · 2021: 46 · 2020: 43 · 2019: 54 · 2018: 51 · 2017: 35 · 2016: 42 · 2015: 45 · 2014: 46 · 2013: 45 · 2012: 43
- FWCI
- 66.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, antidepressant switching, bupropion, sertraline, venlafaxine, treatment-resistant depression, symptom remission, antidepressant response, outpatients
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Remission Induction, Time Factors, Bupropion, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.